Navigation Links
CorVel Announces Second Quarter Revenues and Earnings
Date:11/4/2008

IRVINE, Calif., Nov. 4 /PRNewswire-FirstCall/ -- CorVel Corporation (Nasdaq: CRVL) reported earnings per share of $0.36 for the quarter ended September 30, 2008, compared to $0.40 in the same quarter of the prior year. For the six months ended September 30, 2008 earnings were $0.75 per share compared to the same period in the prior year of $0.79 per share.

The Company reported quarterly revenues of $78 million, up from prior year quarterly revenues of $74 million. For the six months ended September 30, 2008, revenues were $156 million, representing a 6% increase from the $148 million in revenues achieved in the same period of the prior year.

During the quarter the Company continued to expand its Enterprise Comp workers' compensation claims management solutions. Investments have been made in the expansion and strengthening of systems as well as in operations staffing. During the current quarter investments will be focused on the incorporation of artificial intelligence capabilities and workflow management tools CorVel has in the past successfully introduced to its medical review services.

In addition, CorVel's line of directed care networks continued to expand. These services include a growing line of diagnostic imaging, physical therapy, durable medical equipment, independent medical examinations and other ancillary services for workers' compensation claimants. The Company is continuing to add resources to the call centers, software and systems supporting these services. The directed care networks provide preferred appointment scheduling assistance for claimants.

About CorVel

CorVel Corporation (http://www.corvel.com/) is a national provider of leading-edge services and solutions in the field of disability management. CorVel specializes in applying information technology and e-commerce applications to improve healthcare management in the workers' compensation, group health, auto and disability management insurance markets. The Company provides networks of preferred providers, claims administration, case management, utilization management, and medical bill review to more than 2,000 clients nationwide. Leveraging its commitment to flexibility and personal service, CorVel delivers custom solutions for employers, insurers, third party administrators and government entities.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

All statements included in this press release, other than statements or characterizations of historical fact, are forward-looking statements. These forward-looking statements are based on the Company's current expectations, estimates and projections about the Company, management's beliefs, and certain assumptions made by the Company, and events beyond the Company's control, all of which are subject to change. Such forward-looking statements include, but are not limited to, statements relating to the Company's financial statements and business. These forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause the Company's actual results to differ materially and adversely from those expressed in any forward-looking statement.

The risks and uncertainties referred to above include, but are not limited to, factors described in this press release and the Company's filings with the Securities and Exchange Commission, including "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2008. The forward-looking statements in this press release speak only as of the date they are made. The Company undertakes no obligation to revise or update publicly any forward-looking statement for any reason.

CorVel Corporation

Quarterly Results - Income Statement (Unaudited)

Quarter and Six Months Ended September 30, 2007 and 2008

Quarter Ended Quarter Ended

Quarter ended September 30 September 30, 2007 September 30, 2008

Revenues 73,510,000 77,855,000

Cost of revenues 54,856,000 58,996,000

Gross profit 18,654,000 18,859,000

General and administrative 9,398,000 10,722,000

Income from operations 9,256,000 8,137,000

Income tax expense 3,624,000 3,173,000

Net income 5,632,000 4,964,000

Earnings Per Share:

Basic $0.41 $0.36

Diluted $0.40 $0.36

Weighted Shares

Basic 13,889,000 13,764,000

Diluted 14,062,000 13,960,000

Six months Six months

Six months ended September September 30, 2007 September 30, 2008

Revenues 147,847,000 156,056,000

Cost of revenues 111,012,000 117,264,000

Gross profit 36,835,000 38,792,000

General and administrative 18,475,000 21,529,000

Income from operations 18,360,000 17,263,000

Income tax expense 7,167,000 6,732,000

Net income 11,193,000 10,531,000

Earnings Per Share:

Basic $0.80 $0.76

Diluted $0.79 $0.75

Weighted Shares

Basic 13,927,000 13,790,000

Diluted 14,111,000 14,003,000

CorVel Corporation

Quarterly Results - Condensed Balance Sheet (Unaudited)

March 31, 2008 and September 30, 2008

March 31, 2008 September 30, 2008

Cash 17,911,000 23,600,000

Accounts receivable, net 39,164,000 40,950,000

Prepaid expenses and taxes 5,242,000 5,648,000

Deferred income taxes 4,076,000 3,996,000

Property, net 30,569,000 30,209,000

Goodwill and other assets 43,613,000 45,163,000

Total 140,575,000 149,566,000

Accounts and taxes payable 20,475,000 18,797,000

Accrued liabilities 16,473,000 19,030,000

Deferred tax liability 7,249,000 7,245,000

Paid in capital 80,222,000 83,016,000

Treasury stock -162,302,000 -167,511,000

Retained earnings 178,458,000 188,989,000

Total 140,575,000 149,566,000


'/>"/>
SOURCE CorVel Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. CorVel Announces Expanded Share Buyback
2. CorVel Announces Record Earnings
3. CorVel Announces Appearance at Bank of America Health Care Conference
4. CorVel to Present at UBS Global Healthcare Services Conference
5. CorVel Announces Record Earnings Per Share
6. CorVel Corporation Announces Resumption of Stock Repurchases
7. Psychemedics Corporation Announces Third Quarter Results
8. HealthFitness Announces 2008 Third Quarter Results
9. ATS Medical Announces Third Quarter Results
10. STERIS Corporation Announces Webcast of Analyst Conference
11. Barr Announces Approval of Generic Camptosar(R) Injection, 20 mg/mL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... M&S ... Certificate of Conformity for the Smart System® 20/20. CE Certification builds upon M&S's ... standards and specifications such as ANSI, ISO and proven test methods used in ...
(Date:3/27/2017)... PA (PRWEB) , ... March 27, 2017 , ... ... business simulation -centric training, today announced the launch of a new research ... strategy, having the skills needed to execute that strategy, and the actual success ...
(Date:3/27/2017)... ... March 27, 2017 , ... According to the American Cancer ... stages, is more than 95%. Once the cancer spreads to other organs, bones, or ... find out how to avoid this latter group, tune in to Lifestyle Magazine ...
(Date:3/27/2017)... Texas (PRWEB) , ... March 27, 2017 , ... ... at the GTEC Orange facility from 8:00am-10:00am on Monday, April 3rd to commemorate ... and will be an opportunity for area-residents to celebrate two great years while ...
(Date:3/25/2017)... PA (PRWEB) , ... March 25, 2017 , ... Getting ... as a public relations partner. , All through the year, Garden Media aims ... press releases, working with key influencers and pitching client’s key messages to ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... , March 27, 2017  ImMAGE Biotherapeutics (OTCMKTS: ... immunotherapy successfully passed early toxicology and efficacy studies. The ... to target a specific protein, MAGE A, in an ... breast cancer. After 4 weeks of ... to show very little toxicity in a full toxicology ...
(Date:3/27/2017)... , March 27, 2017  Sanderling Ventures, portfolio ... Ethicon, a division of Johnson & Johnson. Torax manufactures ... the treatment of gastro-esophageal reflux disease (GERD). The ... (MSA) technology and the procedure is currently available ... Torax Medical was founded by Sanderling Ventures, ...
(Date:3/27/2017)... TEL AVIV, Israel , March 27, 2017 ... focused on oncology and immunology, announced today that AGI-134, an ... recently announced acquisition of Agalimmune Ltd., will be featured at ... Meeting in Washington, DC to ... ...
Breaking Medicine Technology: